Expanded Access to ABBV-706
NCT07310277 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-01-29
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-706 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
- DRUG
-
ABBV-706
Intravenous (IV) Infusion
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
NCT04227028 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
NCT02475382 ·Status: NO_LONGER_AVAILABLE
-
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
NCT00130780 ·Status: COMPLETED ·Phase: PHASE2
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
NCT07250477 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
NCT02250326 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
NCT06834074 ·Status: AVAILABLE
-
A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC
NCT00369070 ·Status: TERMINATED ·Phase: PHASE2
-
A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC
NCT04807114 ·Status: RECRUITING
-
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
NCT00436332 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer
NCT00717938 ·Status: COMPLETED ·Phase: PHASE3
-
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
NCT01562028 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects
NCT04939662 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840 ·Status: RECRUITING ·Phase: PHASE1
-
Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
NCT01279798 ·Status: NO_LONGER_AVAILABLE
-
T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy
NCT00022243 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
NCT00050830 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
NCT00094094 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
NCT01966003 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
NCT00073723 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT05513703 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
NCT07099898 ·Status: RECRUITING ·Phase: PHASE3
-
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
NCT06064500 ·Status: APPROVED_FOR_MARKETING
-
S0310: Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer
NCT00074295 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
NCT00130728 ·Status: COMPLETED ·Phase: PHASE3